What it's for (Indications)
- Methylergometrine maleate is primarily indicated for the prevention and treatment of postpartum and post-abortion hemorrhage due to uterine atony or subinvolution.
- It is specifically utilized in obstetric settings to manage excessive bleeding following childbirth or miscarriage.
- The drug is administered to enhance uterine tone and promote sustained uterine contractions, which are critical for compressing intramyometrial blood vessels and preventing severe blood loss.
- This includes situations such as uterine atony after the delivery of the placenta, subinvolution of the uterus, and to assist in the expulsion of retained products of conception after an incomplete abortion.
- Its use is crucial in emergencies where rapid control of uterine bleeding is required to preserve maternal health and prevent complications associated with significant hemorrhage, ensuring the integrity of the maternal circulatory system.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of methylergometrine maleate must be carefully managed to ensure efficacy and minimize adverse effects, with administration routes including intramuscular (IM), intravenous (IV), and oral. For acute management of postpartum hemorrhage, a typical IM dose is 0.2 mg administered after the delivery of the anterior shoulder or immediately after the delivery of the placenta. This dose may be repeated every 2 to 4 hours as needed, with a usual maximum of 5 doses in total for the postpartum period. In severe emergency situations or for rapid onset of action, an IV dose of 0.2 mg may be given very slowly over at least 60 seconds, due to the significant risk of sudden, severe hypertension. For sustained uterine contraction and prevention of late postpartum hemorrhage, oral tablets of 0.2 mg are commonly prescribed 3 to 4 times daily for 2 to 7 days postpartum. The precise dosage and duration of treatment should always be determined by the treating physician based on the patient's specific clinical condition, response to therapy, and overall medical history. |
Safety & Warnings
Common Side Effects
- Potential side effects include hypertension (increased blood pressure), temporary chest pain, dizziness, and vomiting.
- Patients experiencing persistent symptoms should consult their doctor.
Serious Warnings
- Black Box Warning: Methylergometrine maleate does not carry a formal FDA-mandated Black Box Warning. However, clinicians must be acutely aware of severe and potentially life-threatening risks associated with its administration, particularly regarding cardiovascular and cerebrovascular events. There is a serious risk of severe hypertension, seizures, and cerebrovascular accidents, including cerebral hemorrhage, especially when the drug is administered intravenously or in patients with pre-existing hypertension, preeclampsia, or eclampsia. Intravenous administration should be reserved exclusively for life-threatening emergencies where rapid uterine contraction is imperative, and must be performed slowly, over no less than 60 seconds, with immediate and continuous monitoring of blood pressure and uterine response. The oral route is generally preferred for routine management due to a lower risk profile for these severe adverse events. Patients with known cardiovascular disease, severe renal impairment, severe hepatic impairment, or sepsis are at significantly increased risk of adverse reactions due to compromised drug metabolism and increased susceptibility to vasoconstrictive effects. The drug is contraindicated for the induction of labor and should not be used in cases of threatened spontaneous abortion, given its potent uterotonic effect which could compromise fetal viability.
- Pregnancy risk cannot be ruled out; consult a doctor before use.
- Avoid driving as it may impair ability.
- Use with extreme caution in patients with sepsis (bacterial infection of the body tissues).
How it Works (Mechanism of Action)
Methylergometrine maleate, an ergot alkaloid derivative, exerts its primary pharmacological action through direct stimulation of the uterine smooth muscle. It acts as an agonist or partial agonist on various receptors, predominantly alpha-adrenergic and serotonergic (5-HT2) receptors, and to a lesser extent, dopamine receptors within the myometrium. This receptor interaction leads to a rapid, sustained, and forceful contraction of the uterine musculature. Unlike oxytocin, which produces rhythmic contractions followed by relaxation, methylergometrine induces a tetanic contraction of the uterus. This sustained myometrial contraction effectively compresses the blood vessels within the uterine wall, thereby reducing blood flow and controlling postpartum or post-abortion hemorrhage. Furthermore, it possesses weak peripheral vasoconstrictive properties, which contribute to its potential to elevate blood pressure, particularly when administered rapidly intravenously. This vasoconstrictive effect is a critical consideration during administration, especially in patients with pre-existing hypertension or cardiovascular disease.
Commercial Brands (Alternatives)
No other brands found for this formula.